Sandoz’s Jubbonti and Wyost Approved as First Interchangeable Biosimilars to Amgen’s Bone Drugs Prolia and Xgeva
XTalks
MARCH 8, 2024
Denosumab is a RANKL (receptor activator of nuclear factor kappa beta ligand) monoclonal antibody that blocks the ability of RANKL to bind to its receptor RANK. Risk factors include aging, hormonal changes, low body weight, low calcium intake and use of certain medications.
Let's personalize your content